Changes in 5f5cad8: update refs

				CD79B.md
			
          @@ -14,14 +14,16 @@ This has clinical and therapeutic implications as it may contribute sensitivity 

           In an inducible mouse model of MYD88-driven DLBCL, CD79B mutations did not accelerate lymphomagenesis but demonstrated an increased sensitivity to pharmacological BTK inhibition.[@flumannInducibleCd79bMutation2024] 

           In a retrospective analysis, younger patients with MCD DLBCL that were treated with ibrutinib had significantly better outcomes.[@wilsonEffectIbrutinibRCHOP2021]

           The most common hotspot mutation in CD79B is at the tyrosine residue 196 (Y196). 

          -This and other common mutations primarily occur in the immunoreceptor tyrosine-based activation motif (ITAM) domain and prevent the negative regulatory feedback provided by Lyn kinase thereby enhancing BCR signaling.[@kimCD79BMYD88Mutations2014; @davisChronicActiveBcellreceptor2010] CD79B is both a recurrent oncogenic signalling node in ABC-DLBCL and an ideal lineage-restricted, rapidly internalizing surface antigen. The antibody–drug conjugate polatuzumab vedotin exploits CD79B surface expression to deliver a cytotoxic payload to malignant B cells, independent of CD79B mutation status[@assiPolatuzumabVedotinCurrent2021].

          -

          -

          +This and other common mutations primarily occur in the immunoreceptor tyrosine-based activation motif (ITAM) domain and prevent the negative regulatory feedback provided by Lyn kinase thereby enhancing BCR signaling.[@kimCD79BMYD88Mutations2014; @davisChronicActiveBcellreceptor2010] 

           ## Experimental Evidence

           Driver mutations affecting this gene in DLBCL have been experimentally demonstrated to cause a gain of function (GOF).[@davisChronicActiveBcellreceptor2010]

          +## Clinical Relevance

          +

          +CD79B is both a recurrent oncogenic signalling node in ABC-DLBCL and an ideal lineage-restricted, rapidly internalizing surface antigen. The antibody–drug conjugate polatuzumab vedotin exploits CD79B surface expression to deliver a cytotoxic payload to malignant B cells, independent of CD79B mutation status[@assiPolatuzumabVedotinCurrent2021]. Polatuzumab vedotin has [FDA approval](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-polatuzumab-vedotin-piiq-diffuse-large-b-cell-lymphoma?utm_source=chatgpt.com) for use *in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies.* More recently, it was [FDA approved](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-polatuzumab-vedotin-piiq-previously-untreated-diffuse-large-b-cell-lymphoma-not?utm_source=chatgpt.com) for use *with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater.*

          +

           ## Relevance tier by entity

           [[include:tables/table1_CD79B.md]]

...	...	@@ -14,14 +14,16 @@ This has clinical and therapeutic implications as it may contribute sensitivity
14	14	In an inducible mouse model of MYD88-driven DLBCL, CD79B mutations did not accelerate lymphomagenesis but demonstrated an increased sensitivity to pharmacological BTK inhibition.[@flumannInducibleCd79bMutation2024]
15	15	In a retrospective analysis, younger patients with MCD DLBCL that were treated with ibrutinib had significantly better outcomes.[@wilsonEffectIbrutinibRCHOP2021]
16	16	The most common hotspot mutation in CD79B is at the tyrosine residue 196 (Y196).
17		-This and other common mutations primarily occur in the immunoreceptor tyrosine-based activation motif (ITAM) domain and prevent the negative regulatory feedback provided by Lyn kinase thereby enhancing BCR signaling.[@kimCD79BMYD88Mutations2014; @davisChronicActiveBcellreceptor2010] CD79B is both a recurrent oncogenic signalling node in ABC-DLBCL and an ideal lineage-restricted, rapidly internalizing surface antigen. The antibody–drug conjugate polatuzumab vedotin exploits CD79B surface expression to deliver a cytotoxic payload to malignant B cells, independent of CD79B mutation status[@assiPolatuzumabVedotinCurrent2021].
18		-
19		-
	17	+This and other common mutations primarily occur in the immunoreceptor tyrosine-based activation motif (ITAM) domain and prevent the negative regulatory feedback provided by Lyn kinase thereby enhancing BCR signaling.[@kimCD79BMYD88Mutations2014; @davisChronicActiveBcellreceptor2010]
20	18
21	19	## Experimental Evidence
22	20
23	21	Driver mutations affecting this gene in DLBCL have been experimentally demonstrated to cause a gain of function (GOF).[@davisChronicActiveBcellreceptor2010]
24	22
	23	+## Clinical Relevance
	24	+
	25	+CD79B is both a recurrent oncogenic signalling node in ABC-DLBCL and an ideal lineage-restricted, rapidly internalizing surface antigen. The antibody–drug conjugate polatuzumab vedotin exploits CD79B surface expression to deliver a cytotoxic payload to malignant B cells, independent of CD79B mutation status[@assiPolatuzumabVedotinCurrent2021]. Polatuzumab vedotin has [FDA approval](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-polatuzumab-vedotin-piiq-diffuse-large-b-cell-lymphoma?utm_source=chatgpt.com) for use in combination with bendamustine and a rituximab product for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, after at least two prior therapies. More recently, it was [FDA approved](https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-polatuzumab-vedotin-piiq-previously-untreated-diffuse-large-b-cell-lymphoma-not?utm_source=chatgpt.com) for use with a rituximab product, cyclophosphamide, doxorubicin, and prednisone (R-CHP) for adult patients who have previously untreated diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or high-grade B-cell lymphoma (HGBL) and who have an International Prognostic Index (IPI) score of 2 or greater.
	26	+
25	27	## Relevance tier by entity
26	28
27	29	[[include:tables/table1_CD79B.md]]